Harmony Biosciences Holdings, Inc. is a publicly traded pharmaceutical company founded in 2017. Headquartered in Plymouth Meeting, Pennsylvania, the company trades on the Nasdaq under the ticker HRMY. As of early 2026, Harmony Biosciences had approximately 293 employees. The company reported revenues of $868.5 million for the full year 2025 and reiterated guidance for its primary product to exceed $1 billion in net revenue for 2026. Its market capitalization was approximately $1.8 billion in late April 2026.
Harmony Biosciences is a commercial-stage pharmaceutical company that develops and commercializes therapies for rare neurological diseases. The company's sole commercial product is WAKIX® (pitolisant), a treatment for excessive daytime sleepiness or cataplexy in adult and pediatric patients with narcolepsy. Harmony Biosciences holds an exclusive license from Bioprojet Société Civile de Recherche to develop, manufacture, and commercialize pitolisant in the United States. The company is also advancing a pipeline of other drug candidates for neurological disorders, including potential treatments for rare epilepsy syndromes.
As an operating pharmaceutical company, Harmony Biosciences' patent litigation posture appears to be that of a brand-name drug manufacturer protecting its key asset. The company's litigation history in the provided database shows it as a plaintiff in one case and never as a defendant. This is consistent with a strategy of enforcing its patent rights against potential generic competitors.
The single tracked case, Harmony Biosciences Management Inc et al. v. AET Pharma US Inc et al., filed in the District of Delaware in April 2026, reflects this posture. According to public financial disclosures, Harmony has settled with six of seven filers of Abbreviated New Drug Applications (ANDAs) for generic versions of WAKIX®, securing its product from generic competition until at least September 2029.